Shawn Cross - 23 Apr 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: PCRX
Reported as of: 23 Apr 2026
Net transaction value: -$325,596
SEC form: 4
Accepted by SEC: 24 Apr 2026, 20:41:26 UTC
Prior SEC filing: 22 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kristen Williams, Attorney-in-Fact

Key filing fact

Shawn Cross filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 24 Apr 2026.

Key facts

This page summarizes Shawn Cross's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Apr 2026, 20:41.

Change

Previous filing in this sequence was filed on 22 Apr 2026.
Current net transaction value: -$325,596.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001734779 Primary reporting owner

Cross Shawn

Relationship: Chief Financial Officer
Address: C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE
Signature: /s/ Kristen Williams, Attorney-in-Fact
Signature date: 24 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCRX transaction

Common Stock

Options Exercise

Transaction value
Shares: +12,941
Change %: +12%
Price: $16.45^*
Shares after: 118,282
Date: 23 Apr 2026
Ownership: Direct
Footnotes: F1

PCRX transaction

Common Stock

Sale

Transaction value: $325,596
Shares: -12,941
Change %: -11%
Price: $25.16
Shares after: 105,341
Date: 23 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCRX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -12,941
Change %: -7.9%
Price: $0.000000^*
Shares after: 150,000
Date: 23 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,941
Exercise price: $16.45
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.